John Mann

Executive Vice President, North American Operations

John Mann has over 24 years of working in CROs and 15 years of experience working in senior leadership roles including Quintiles (now IQVIA), INC Research (now Syneos), PRA Healthsciences, and ICON. He has worked across a diverse range of therapeutic areas and business groups, most recently as Vice President of Emerging Biotech and Rare Disease Operations, and Vice President of Decentralized Clinical Trials (DCTs) Operations at ICON.

John’s experience includes:

• 20+ years in project management and clinical research with 25+ years of management and leadership experience
• Worked on clinical studies in over 50 countries conducting Phase I through IV  studies (primarily I-III, non EDS) including all service areas
• 13+ years of pediatric and rare disease experience in global studies
• Therapeutic experience;
  • Women’s health – Osteoporosis, Oral Contraceptive, Hormone Replacement, Breast cancer, Endometrial safety, Female Sexual Dysfunction, Vasomotor
  • Endocrine/Metabolic/NeuroMuscular – Diabetes– Type I and II, MPS-IV (Morquio syndrome), LAL Deficiency, Precocious Puberty, GVHD, Pompe’s Disease, Spinal Muscular Atrophy (SMA), Phenylketonuria (PKU), Limm Girdle MD,
  • Immunology – Osteoarthritis, Rheumatoid Arthritis, Ménière’s disease
  • Dermatology – Head Lice, Acne, Psoriasis, Epidermolysis Bullosa
  • Cardiovascular – Pulmonary Arterial Hypertension (PAH), Hypertension, Coronary Artery Disease, Cardiac Imaging, Fibrin Sealant
  • Respiratory – Asthma, seasonal allergy